30-Second Takeaway
- Oral semaglutide lowered HF events and MACE in high-risk T2D without excess serious adverse events.
- SGLT2 inhibitors provided robust kidney and survival benefits, including in rapid decliners and nonalbuminuric CKD.
- Metformin use in pregnancy did not increase congenital malformations and may be protective versus insulin.
- CGM readings <70 mg/dL in non-ICU inpatients were too inaccurate to guide insulin therapy alone.
- Albuminuria and clustered metabolic traits substantially increased fracture risk, especially in non-obese T2D.
Week ending February 7, 2026
Targeted cardiorenal, pregnancy, inpatient, and fracture-risk insights for high‑risk diabetes care
Oral semaglutide reduces heart failure events in high-risk T2D, particularly HFpEF
In SOUL’s secondary analysis, oral semaglutide reduced the composite of HF hospitalization, urgent HF visit, or CV death in T2D with prior HF (HR 0.78, 95% CI 0.63–0.96). Benefits were strongest in HFpEF (HR 0.59, 95% CI 0.39–0.86) and not evident in HFrEF (HR 0.98, 95% CI 0.70–1.38). MACE reduction with semaglutide was similar regardless of HF history, supporting use across HF phenotypes for ASCVD/CKD risk. Serious adverse events in participants with HF were comparable between semaglutide and placebo, supporting safety in this population.
Prenatal metformin appears safe for congenital malformations and may be protective vs insulin
This meta-analysis found prenatal metformin exposure was associated with fewer overall congenital malformations than insulin (RR 0.83, 95% CI 0.71–0.99). Drug-target Mendelian randomization showed several metformin-related genes with protective associations for circulatory and musculoskeletal malformations. Placental eQTL validation supported the direction of key protective gene–malformation associations, strengthening causal inference. Together, clinical and genetic data support metformin’s fetal safety regarding congenital malformations when used for GDM or related indications.
SGLT2 inhibitors outperform DPP4 inhibitors on kidney outcomes across prior eGFR slopes
In a propensity-matched real-world cohort of 4,011 T2D patients, SGLT2 inhibitors slowed eGFR decline versus DPP4 inhibitors across baseline eGFR-slope categories. SGLT2i use was associated with lower risk of major adverse kidney events (HR 0.77, 95% CI 0.64–0.94) and abrupt kidney decline (HR 0.76, 95% CI 0.60–0.97). Persistent rapid eGFR decline was also less frequent with SGLT2i (HR 0.76, 95% CI 0.68–0.84), independent of prior eGFR trajectory. Benefits were similar even when past eGFR slope was modeled continuously, supporting SGLT2i as preferred kidney-protective therapy over DPP4i.
CGM is unreliable for detecting inpatient hypoglycemia on general wards
This systematic review included nine studies with 465 paired hypoglycemic CGM and reference glucose values in non-ICU inpatients with diabetes. Mean and median absolute relative differences in the hypoglycemia range were frequently high, often exceeding 15%. Reported error ranged widely, with mean absolute relative differences up to 53.3% in some studies. The authors conclude that CGM readings below 70 mg/dL are too inaccurate to guide hospital insulin therapy without confirmatory blood glucose.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.